QCG
CSTL icon

Quadrant Capital Group’s Castle Biosciences CSTL Stock Holding History

Quadrant Capital Group’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-336
Closed -$8.25K – 1549
2026
Q1 		$8.25K Hold
336
– – ﹤0.01% 2240
2025
Q4 		$13.1K Hold
336
– – ﹤0.01% 2132
2025
Q3 		$7.65K Buy
+336
New +$6.83K ﹤0.01% 2232
2022
Q2 		– Sell
-66
Closed -$3K – 2574
2022
Q1 		$3K Buy
+66
New +$2.73K ﹤0.01% 2042

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrant Capital Group's CSTL Position: Q2 2026 in Review

Quadrant Capital Group sold out of Castle Biosciences (CSTL) in Q2 2026, closing a stake of 336 shares — an estimated $8.25K sold.

Quadrant Capital Group first reported a position in CSTL in Q1 2022 and held it in 4 quarters. The position peaked at $13.1K in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Quadrant Capital Group reported no remaining Castle Biosciences position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 336 Castle Biosciences shares in Q2 2026, an estimated $8.25K.
  • Quadrant Capital Group first reported a position in Castle Biosciences in Q1 2022 and held it in 4 quarters.
  • Quadrant Capital Group's Castle Biosciences position peaked at $13.1K in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.